Table 3.
Quality adjusted life years (QALYs), costs, and cost effectiveness at three years for all patients (n=613) randomised to treatment with endovascular strategy (endovascular repair if aortic morphology is suitable, open repair if not). Results are reported after multiple imputation
| Endovascular strategy | Open repair | Mean difference (95% CI) | P value | ||||
|---|---|---|---|---|---|---|---|
| No of patients | Mean (SD) | No of patients | Mean (SD) | ||||
| Life years | 316 | 1.72 (1.43) | 297 | 1.61 (1.41) | 0.115 (−0.110 to 0.341) | 0.314 | |
| QALYs* | 316 | 1.14 (1.03) | 297 | 0.97 (1.02) | 0.166 (0.002 to 0.331) | 0.048 | |
| Total cost (£) | 316 | 16 878 (19 624) | 297 | 19 483 (22 412) | −2605 (−5966 to 702) | 0.120 | |
| Incremental net benefit (£)† | — | — | — | — | 7637 (1820 to 13 454) | 0.005 | |
*Includes patients who died and those without proved rupture, who were assumed to have, on average, same quality of life of elective repair patients.12 QALYs between 1 and 3 years discounted with NICE’s recommended discount rate of 3.5%.
†Incremental net benefit for endovascular versus open repair calculated by multiplying mean difference in QALY by NICE’s recommended willingness to pay threshold (£30 000 per QALY gain) and subtracting from this incremental cost.